Foreign capital enterprise's medicine, even exceed the patent period, the medicine price which Chinese enterprises manufactured with the same varieties is 41.3% than foreign capital enterprise's price, some even just about 10% of a foreign-capital enterprise's. And this is aimed at "separate pricing" product adjustment,it is expected to further adjust chinese-foreign medicine enterprises' balance.
Depreciating group after group at different times in future.
But the above domestic manufacturer's views are not approved by foreign-capital enterprise.
Yesterday, a executives of China Association of Enterprises with Foreign Investment (CAEFI) drug research and development industry committee (RDPAC) indicate that Compared with international,our copy drug price is 22%~30% of international general price leve, which based on the original drug price adjustment would restain industry quality system input, against our country medicine market and the healthy development of the pharmaceutical industry.
For multinational pharmaceutical enterprise,due to a new drug of its r&d input is more than $1 billion basically, such a great investment need great number of expenses for medicine to give in return.
手工翻譯,供參考!